Compounded GLP-1 Medication, Explained

What compounding means

Compounding is the preparation of a medication by a licensed pharmacy to meet a specific patient need, rather than manufacture of a mass-produced product by a drug company. It is an old and ordinary part of American pharmacy — it is how a child gets a liquid version of a tablet, how someone with a dye allergy gets a formulation without it, and how a dose that does not exist commercially gets made.

A compounded GLP-1 contains the same active pharmaceutical ingredient — semaglutide or tirzepatide — as its brand-name counterpart. What differs is who prepares it, in what quantities, and under which section of federal law.

The two kinds of compounding pharmacy

Both are legal and both are regulated — but they are regulated differently, and 503B facilities are held to the tighter federal standard. This is the single most useful question to ask any telehealth provider: which type of pharmacy fills my prescription, and can you name it? A provider that will not answer that plainly is telling you something. It is one of fourteen questions in How to Choose a GLP-1 Telehealth Provider.

The honest regulatory picture

Compounded medications are not FDA-approved products. That phrase sounds alarming and is worth unpacking, because it does not mean unregulated or untested — it means something specific.

• FDA approval applies to a *finished product* from a specific manufacturer, following that manufacturer's own clinical trials. Compounded preparations are made per prescription and so are never submitted for that approval.
• The active ingredient is not exempt from oversight: it must come from an FDA-registered facility, and it is the same molecule studied in the trials described in The Complete Guide to GLP-1 Medications.
• The pharmacy is licensed and inspected — by a state board for 503A, by the FDA itself for 503B.
• What compounded medication lacks is a manufacturer-run trial of that particular preparation. That is a genuine difference, and it is fair to weigh it.

There is also a regulatory history worth knowing. During the GLP-1 shortages of 2022–2024, compounding of these medications expanded substantially under the shortage provisions of federal law. Those shortages were subsequently declared resolved, and the grounds for compounding narrowed accordingly — compounding now proceeds on the basis of documented clinical need and individualised prescribing rather than shortage. Any provider still describing the shortage era as though it were current is not keeping up.

Compounded versus brand name

The cost gap is the reason this option exists at all, and it is not small. The full arithmetic — including what a year actually costs each way — is in What GLP-1 Medication Costs in 2026.

Questions worth asking any provider

1. Which pharmacy fills this, and is it 503A or 503B? You are entitled to a specific answer, not a category.
2. Where does the active ingredient come from? It should be an FDA-registered source, and they should be able to say so.
3. Is there a certificate of analysis for the batch? Reputable compounders test potency and sterility and can produce documentation.
4. Is the physician licensed in my state? They must be. Ask for the name.
5. Is anything added to it? Some compounded preparations include additives such as B12 or amino acids. There is nothing sinister about that, but you should know what you are injecting and why.
6. What happens if I need to stop? Ask about cancellation before you start, not after. Our answer: no long-term contract, cancel any time.

Common questions